Devers Shannon L. 4

Accession 0000874015-26-000029

CIK 0000874015other

View on SEC.gov Company Profile

Filed

Jan 8, 7:00 PM ET

Accepted

Jan 9, 5:08 PM ET

Size

28.6 KB

Accession

0000874015-26-000029

Insider Transaction Report

Form 4

Period: 2026-01-07

IONIS PHARMACEUTICALS INCIONS

Devers Shannon L.

EVP, Chief Human Resources Ofc

Transactions

Exercise/Conversion
Common Stock
2026-01-07$56.78/sh+25,545$1,450,445→ 43,039 total
Sale
Common Stock
2026-01-07$85.36/sh−25,545$2,180,521→ 17,494 total
Exercise/Conversion
Common Stock
2026-01-07$32.60/sh+2,101$68,493→ 19,595 total
Sale
Common Stock
2026-01-07$85.36/sh−2,101$179,341→ 17,494 total
Exercise/Conversion
Common Stock
2026-01-07$32.60/sh+3,460$112,796→ 20,954 total
Sale
Common Stock
2026-01-07$84.62/sh−3,460$292,785→ 17,494 total
Exercise/Conversion
Common Stock
2026-01-07$37.58/sh+3,829$143,894→ 21,323 total
Sale
Common Stock
2026-01-07$84.62/sh−3,829$324,010→ 17,494 total
Exercise/Conversion
Common Stock
2026-01-07$52.87/sh+9,264$489,788→ 26,758 total
Sale
Common Stock
2026-01-07$84.62/sh−9,264$783,920→ 17,494 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-01-07−2,101→ 11,339 total
Exercise: $32.60From: 2023-01-03Exp: 2032-01-02→ Common Stock (2,101 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-01-07−3,460→ 7,879 total
Exercise: $32.60From: 2023-01-03Exp: 2032-01-02→ Common Stock (3,460 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-01-07−3,829→ 9,254 total
Exercise: $37.58From: 2024-01-03Exp: 2033-01-02→ Common Stock (3,829 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-01-07−9,264→ 9,262 total
Exercise: $52.87From: 2024-01-02Exp: 2034-01-01→ Common Stock (9,264 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-01-07−25,545→ 2,971 total
Exercise: $56.78From: 2022-01-04Exp: 2028-01-03→ Common Stock (25,545 underlying)

Footnotes (3)

[F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.10 to $85.64 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.08 to $85.08 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

IONIS PHARMACEUTICALS INC

CIK 0000874015

→

Entity typeother

Related Parties

filerCIK 0002037721

Filing Metadata

Form type: 4
Filed: Jan 8, 7:00 PM ET
Accepted: Jan 9, 5:08 PM ET
Size: 28.6 KB

View on SEC.gov